OTCPicks.com: OTCPicks.com Daily Market Movers Digest Midday Report for Wednesday, January 7th PGOG, ICOG, ADXS, ILNS

Wed. January 07, 2009; Posted: 11:59 AM

Visit http://www.otcpicks.com/microcap.htm to register for our Daily Market Mover's Digest Newsletter and Email Stock Watch Alerts.

PERF GO GREEN HOLDINGS INCORPORATED (OTCBB: PGOG)

Detailed Quote: http://www.otcpicks.com/quotes/PGOG.php

Company Profile: http://www.otcpicks.com/perf-go-green/perf-go-green.htm

Perf Go Green Holdings, Inc. is engaged in the creation and global marketing of 100% eco-friendly, non-toxic, food-contact-compliant, biodegradable plastic products. All Perf Go Green products are made from recycled plastics and completely break down in landfill within two years, leaving no toxic or visible residue, as compared to other plastics that take hundreds of years. Perf Go Green's corporate name reflects its "Go Green" mission to develop, market and distribute biodegradable plastic products as a practical and viable solution to eliminating plastic waste from the world environment.

PGOG News:

January 6 - Perf Go Green Partners With Five Star Products, Inc.

Perf Go Green Holdings, Inc. (OTCBB: PGOG | Quote | Chart | News | PowerRating) (www.perfgogreen.com), a marketer and distributor of biodegradable plastics, has entered into a distribution agreement with Five Star Products, the leading supplier of paint and hardware to Independent retailers in the mid-Atlantic states. Five Star supplies products to approximately 2,500 dealers from Maine to South Carolina.

Beginning this month, Five Star will offer a full array of Perf Go Green products, including household trash bags, drop cloths, pet products and commercial can liners.

"Five Star is a great addition to Perf Go Green's distribution network," commented Perf Go Green Chairman and CEO Tony Tracy. "It's well-known in the industry for its interest in innovative products and its buyers have a continuous eye to the future. Perf Go Green's market-leading biodegradable plastic products are a perfect fit with Five Star's goal of putting exciting new products on its customers' shelves. We look forward to making our earth-friendly products available to many more consumers through our partnership with this pioneering distributor."

"Five Star is excited about adding Perf Go Green to our list of products," said Bruce Sherman, CEO of Five Star. "Environmentally-friendly products have a place on the shelves of every store. Homeowners and businesses concerned about our environment are looking for products that can have a positive impact on preserving and improving it. Five Star will provide a distribution channel that can place Perf Go Green products in a variety of retail outlets extending from Maine to South Carolina."

In business for nearly 100 years, Five Star is a wholesale distributor of home decorating, hardware, and finishing products in the U.S. The company distributes its products to retail dealers, including lumber yards, do-it yourself centers, independent hardware stores, and paint stores, from Maine to South Carolina. It currently operates two distribution centers, located in Newington, Connecticut and East Hanover, New Jersey.

Perf Go Green's corporate name reflects its "Go Green" mission to develop, market and distribute biodegradable plastic products as a practical and viable solution to eliminating plastic waste from the world environment. Founded in November 2007, Perf Go Green premiered at the March 2008 International Home and Housewares Show in Chicago, where its products were honored for their design quality and innovation. Perf Go Green's household products are now available at stores with more than 22,000 retail units and online at Amazon.com and drugstore.com. The company also markets a wide array of commercial trash bags.

ICO GLOBAL COMMUNICATIONS LIMITED (NASDAQ: ICOG | Quote | Chart | News | PowerRating) "Up 27.27% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/ICOG.php

ICO Global Communications (Holdings) Limited, a development stage company, provides mobile satellite services (MSS) using geosynchronous earth orbit satellite in the United States and internationally. It operates a medium earth orbit satellite system in the 2 GHz band that provides data gathering services. The company also develops a hybrid MSS/ATC System with satellite and terrestrial communications capabilities. Its MSS/ATC System allows providing wireless voice, video, data, and Internet service on mobile and portable devices. The company was founded in 1995 and is based in Reston, Virginia.

ICOG News:

January 7 - ICO G1 Space Segment Testing Complete

Worlds First Commercial Two-Way Ground Based Beam Forming System Now Set for Alpha Trials of Combined Satellite-Terrestrial Mobile Services

ICO Global Communications (Holdings) Limited (Nasdaq: ICOG | Quote | Chart | News | PowerRating) announced that ICO G1 satellite In Orbit Testing (IOT) and testing of the innovative Ground Based Beam Forming (GBBF) system for the ICO Space Segment are both now complete, and the company's subsidiary, ICO Satellite Services G.P., has accepted the Space Segment from Space Systems/Loral. Launched from Cape Canaveral, Florida on April 14, 2008, ICO G1 is the world's first satellite to utilize a two-way GBBF system. Delivered and integrated at ICO's gateway in North Las Vegas, GBBF delivers unprecedented flexibility to provide next-generation mobile satellite services. Alpha trials featuring ICO's satellite-terrestrial network are underway in Las Vegas, Nevada and Raleigh-Durham, North Carolina.

"ICO G1's satellite and GBBF performance has been remarkable throughout the testing period," commented Bob Day, ICO senior vice president for space systems. "ICO is well-positioned to use the most innovative commercial satellite ever deployed for delivering a wide range of nationwide interactive mobile services."

"We have begun using ICO G1 in conjunction with our terrestrial network and mobile devices in Las Vegas and Raleigh-Durham to test and refine our innovative MSS/ATC services, including ICO mim," said David Zufall, senior vice president of network systems for ICO.

Designed and built by Space Systems/Loral (SS/L), a subsidiary of Loral Space & Communications (Nasdaq: LORL), ICO G1 has 250 fully configurable transmit and receive beams. SS/L is the first company to successfully develop a two-way GBBF system, and a patent is pending for the company's invention of the technology. With GBBF, spot beams can be added, removed or reconfigured to enable a satellite to operate from different orbital locations and to adapt to changes in traffic patterns or to provide new applications. With beam forming performed on the ground, the cost and time to deliver a highly flexible satellite are significantly reduced. The satellite employs a large 12-meter mesh antenna reflector, which is essential for delivering services to small mobile and portable devices.

"The GBBF implementation for ICO G1 demonstrates Space Systems/Loral's ability to develop new technologies in a commercial environment," said Christopher Hoeber, senior vice president of program management and systems engineering for Space Systems/Loral. "With our GBBF architecture, ICO G1 can deliver unparalleled flexibility."

Hughes Network Systems, LLC (Hughes) (Nasdaq: HUGH) developed and implemented the high-speed signal conditioning and processing ground equipment that enables GBBF.

Matthew Mohebbi, vice president and general manager of the Mobile Satellite business unit at Hughes, stated, "We are very pleased to reach this milestone with ICO. Hughes provided the RF terminals for the Ground Based Beam Forming system to Space Systems/Loral (SSL). We worked closely with ICO and SSL to complete over-the-air testing of ICO G1."

ABOUT SPACE SYSTEMS/LORAL

Based in Palo Alto, California, SS/L designs and builds satellites and spacecraft systems for commercial and government customers around the world. As the leading provider of commercial satellites, the company works closely with satellite operators to deliver spacecraft for a broad range of services including direct-to-home television, digital audio radio, broadband Internet, and digital multimedia broadcasting. With more power on orbit than any other satellite manufacturer, SS/L helps customers meet business objectives with advanced solutions based on space-proven heritage designs.

ABOUT LORAL SPACE & COMMUNICATIONS

Loral Space & Communications is a satellite communications company. Through its Space Systems/Loral subsidiary, the company is a world-class leader in the design and manufacture of satellites and satellite systems for commercial and government applications including direct-to-home television, broadband communications, wireless telephony, weather monitoring and air traffic management. Loral also owns 64 percent of Telesat Canada, one of the world's largest providers of satellite services. Telesat Canada operates a fleet of telecommunications satellites used to broadcast video entertainment programming, distribute direct-to-home video and broadband data services, and other value-added communications services.

ABOUT HUGHES NETWORK SYSTEMS

Hughes Network Systems, LLC (HUGHES) is the global leader in providing broadband satellite networks and services for large enterprises, governments, small businesses, and consumers. HughesNet encompasses all broadband solutions and managed services from Hughes, bridging the best of satellite and terrestrial technologies. Its broadband satellite products are based on global standards approved by the TIA, ETSI and ITU standards organizations, including IPoS/DVB-S2, RSM-A and GMR-1. To date, Hughes has shipped more than 1.5 million systems to customers in over 100 countries.

Headquartered outside Washington, D.C., in Germantown, Maryland, USA, Hughes maintains sales and support offices worldwide. Hughes is a wholly owned subsidiary of Hughes Communications, Inc. (Nasdaq: HUGH).

ADVAXIS INCORPORATED (OTCBB: ADXS | Quote | Chart | News | PowerRating) "Up 25.00% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/ADXS.php

Based in North Brunswick, New Jersey, Advaxis is developing proprietary Listeria monocytogenes ("Lm") cancer vaccines based on technology developed by Dr. Yvonne Paterson, Professor of Microbiology at the University of Pennsylvania and Chairperson of Advaxis' Scientific Advisory Board. Advaxis is developing attenuated live Listeria-based vaccines that deliver engineered tumor antigens, which safely stimulate multiple simultaneous immunological mechanisms to fight cancer. Advaxis' lead Listeria vaccine candidate, Lovaxin-C, targets human papilloma virus ("HPV")-associated cancers such as cervical and head and neck. Current Lm vaccines in development target prostate, breast, ovarian and other cancers. Recently, Advaxis completed a Phase I clinical trial of Lovaxin-C. A Phase II clinical trial is planned for patients with cervical intraepithelial neoplasia ("CIN"). The Lm platform also has applications in the fields of infectious disease and autoimmune disorders.

ADXS News:

January 6 - Advaxis Phase II Clinical Trial HOLD Lifted U.S. FDA Approves Investigational New Drug Application for Phase II for Cervical Intraepithelial Neoplasia Grade 2/3 Clinical Trial

Advaxis Inc. (OTCBB: ADXS), a biotechnology company, received permission from the U. S. Food and Drug Administration (FDA) to test its lead drug candidate, Lovaxin C, in patients with grade 2/3 cervical intraepithelial neoplasia (CIN). With this approval of the Investigational New Drug (IND) application for Lovaxin C, the FDA "HOLD" on Advaxis' clinical program has been lifted.

Advaxis submitted its IND application to the FDA in May 2008, which outlined the proposed protocol for a Phase II clinical trial safety study targeting CIN - a precursor condition to cervical cancer, commonly diagnosed by PAP smears. The proposed trial, unlike Advaxis' Phase I cervical cancer trial, will target the disease at a much earlier stage of development and recruit CIN patients living in the U. S. that are otherwise healthy. Due to the different patient population, the FDA requested more information to support the safety of Lovaxin-C and the methods used in its manufacture, which prompted the clinical trial "HOLD."

Regarding the FDA's acceptance of the Company's IND application, Advaxis' Executive Director of Product Development, Dr. Christine Chansky, MD, JD, said, "Advaxis' clinical and scientific team comprehensively responded to the FDA's questions. There were well over 700 pages of documentation submitted, which included results from our Phase I clinical trial study as well as animal research conducted specifically for the response. It was a great job by the team and a fine start to our regulatory relationship with the FDA. The FDA has requested additional information regarding our manufacturing processes as they develop, which we will provide as the processes are validated."

Addressing the CIN trial's expectations, Advaxis' Executive VP of Science & Operations Dr. John Rothman commented, "This study is a blinded, randomized and placebo-controlled trial of sufficient size; to build upon the promising results of our Phase I study in metastatic cervical cancer patients. In this study however, we are treating healthier women with stronger immune systems and with much less disease burden. We believe that this work will provide us with meaningful support that our live, Listeria-based drug delivery system can safely resolve CIN before it becomes invasive cervical cancer, and without the adverse events that currently attend surgical treatment." The Company anticipates commencing the trial in the second or third quarter of 2009.

CIN is a cervical condition caused by the sexually transmitted human papilloma virus ("HPV"), which can lead to invasive cervical cancer, if not diagnosed properly and left untreated. Recently developed vaccines can prevent disease if administered before HPV is contracted but do not treat the disease, and cannot be used to treat women who have already been exposed to HPV. Today, the accepted treatment protocol for late stage CIN is surgery, which is performed to preclude invasive cancer. Surgical treatment of CIN is associated with various adverse events and may render the cervix incompetent to come to a full term pregnancy.

"The FDA's approval of Advaxis' IND application to conduct the first US based clinical trial of a live Listeria monocytogenes vaccine that secretes an LLO-tumor specific antigen fusion is a major milestone for the Company as well as for the entire field of immunotherapy," commented Advaxis Inc.'s Chairman and CEO, Thomas A. Moore. "Our technology enables the delivery of a tumor specific antigen fused to the highly adjuvant Listeria protein, Listeriolysin O ("LLO"), which has a very powerful, anti-tumor effect. Although we have an active clinical program in invasive cervical cancer planned, the safety and efficacy results in the CIN indication will enable us to pursue a U. S. market of about 250,000 patients per year; 50 times the market size of cervical cancer."

ABOUT THE LOVAXIN-C VACCINE

Advaxis' technology platform uses modified Listeria monocytogenes to deliver a tumor-specific antigen fusion protein. Bioengineered Listeria that are attenuated and secrete Advaxis' proprietary fusion protein, have the ability to generate a robust immune response, break immune tolerance to cancer and produce an unusually strong and effective multi-level therapeutic immune response to existing cancer and other diseases.

Advaxis' Listeria-based technology is based on over a decade worth of work by Dr. Yvonne Paterson in her laboratory at the University of Pennsylvania. The Company's proprietary antigen fusion protein technology, stimulates innate immunity, both arms of the adaptive cellular immune system, suppresses regulatory T-cells that inhibit many vaccines in the function of activated tumor-killing cells and has other anti-tumor effects.

Unlike prophylactic vaccines, Lovaxin-C was designed to treat women who have already developed cervical cancer as a result of contracting an HPV infection, which is the most prevalent sexually transmitted disease in the US. Current products on the market are ineffective in treating HPV-infected women.

INTELLECT NEUROSCIENCES (OTCBB: ILNS | Quote | Chart | News | PowerRating) "Up 11.76% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/ILNS.php

Intellect Neurosciences, Inc., a biopharmaceutical company, engages in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease and other disorders of the central nervous system. The company's product pipeline includes small molecules, monoclonal antibodies, and vaccines that address unmet needs in Alzheimer's disease and other indications, including ataxia, Parkinson's disease, Huntington's disease, diabetes, stroke, myelodysplastic syndromes, motor neuron disease (ALS and Lou Gehrig's disease), and radiation injury. Its lead drug candidate, OXIGON, is a chemically synthesized form of a small, potent, dual mode of action, naturally occurring molecule with potential as a disease-modifying agent for Alzheimer's disease and other therapeutic indications. OXIGON has completed human Phase Ia clinical trials. Intellect Neurosciences also develops immunotherapies (monoclonal antibodies and vaccines) to prevent or arrest the progression of Alzheimer's disease, while avoiding the risk of adverse reactions. The company also has various proprietary immunotherapy platforms, such as ANTISENILIN, RECALL-VAX, and BETA-VAX with patented drug candidates for both passive and active immunization against Alzheimer's disease. ANTISENILIN is a passive monoclonal antibody platform, and RECALL-VAX and BETA-VAX are platform technologies for vaccination. The company was founded in 2005 and is headquartered in New York, New York.

ILNS News:

April 10 - Intellect Neurosciences, Inc. Grants to Top Tier Global Pharmaceutical Company License to Certain Alzheimer's Patents and Patent Applications

Intellect Neurosciences, Inc. (OTCBB: ILNS), a biopharmaceutical company focused on development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease (AD), announced today that it has granted a non-exclusive License to a top-tier global pharmaceutical company regarding certain of Intellect's patents and patent applications related to antibodies and methods of treatment for Alzheimer's disease and to make, have made, use, sell, offer to sell and import certain licensed products. The grant of the License follows the exercise by this top-tier global pharmaceutical company of the option (the "Antibody Option") that it acquired from Intellect pursuant to an Option Agreement executed by Intellect and the top-tier global pharmaceutical company (the "Optionee") in October 2008.

Intellect is entitled to a license fee upon the exercise of the Antibody Option by the Optionee. In addition, Intellect may be entitled to future patent based milestone payments and royalties from potential future drug sales by the Optionee. Recently, Intellect received its first milestone payment under its license agreement with Wyeth (NYSE: WYE) and Elan Pharma International Ltd. (NYSE: ELN) as a result of obtaining the grant of a European patent and may be entitled to additional payments from Wyeth and Elan in the future.

Dr. Daniel Chain, Intellect's Chairman and CEO and inventor of the licensed patents and patent applications, commented: "We are gratified to see our approach being used by major pharmaceutical companies to combat Alzheimer's disease. Alzheimer's patients need strong and capable partners in their fight to overcome this devastating disease and we are pleased to enter into this second license agreement with a top-tier global pharmaceutical company for our patent estate relating to the use of monoclonal antibodies designed to slow or arrest progression of the disease. We believe that several therapeutic agents may be necessary to fully treat the AD population and that our licensing efforts, together with our internal development programs, will increase the likelihood of developing safe and effective therapies."

Intellect to Participate in Goldman Sachs "Healthcare CEOs Unscripted" Conference

Dr. Daniel Chain, Chairman and Chief Executive Officer of Intellect, will be participating on a CEO/Industry Panel discussing Drug Development in Alzheimer's Disease at Goldman Sachs' "Healthcare CEOs Unscripted Conference: A View from the Top", on Thursday January 8, 2009 at 2:00PM. The conference is being held at the Goldman Sachs Conference Center, 32 Old Slip, New York, NY.

ABOUT INTELLECT'S IMMUNOTHERAPY PLATFORMS FOR ALZHEIMER'S DISEASE

Intellect's immunotherapy platforms aim to prevent the accumulation of aggregated beta amyloid protein fragments in the brain that are thought to be the root cause of Alzheimer's disease. In healthy people, beta amyloid does not aggregate but in Alzheimer's patients it clumps first to form long fibrils, like tentacles, that eventually deposit on the surface of nerve cells as a spaghetti-like protein mass called amyloid plaques. The beta amyloid fragments are generated as a product of metabolism from the much larger Amyloid Precursor Protein which is present in most tissues in the body and implicated in numerous important physiological functions. Intellect's immunotherapy approach for Alzheimer's disease involves making an antibody molecule available to bind to the beta-amyloid toxin, thus promoting its clearance away from sites of damage in the brain. This therapeutic outcome can be potentially achieved either by administering an externally generated monoclonal antibody (passive immunization) or by provoking the patient's immune system to generate such an antibody (active immunization). Both approaches have the potential to slow or arrest disease progression provided that key safety issues are addressed. Of particular importance is the need to avoid interfering with the physiological roles of the Amyloid Precursor Protein. Intellect's has incorporated proprietary safety features into its ANTISENILIN monoclonal antibody and RECALL-VAX(TM) technology platforms for both passive and active immunization, respectively to minimize the potential for adverse side-effects by generating antibodies that bind only the toxic beta amyloid and not the Amyloid Precursor Protein. These features and supporting patent position provides the Company with a strong competitive advantage in this field.

ABOUT ALZHEIMER'S DISEASE

Alzheimer's disease, the most common form of dementia, is characterized by progressive loss of memory and cognition, ultimately leading to complete debilitation and death. A hallmark feature of Alzheimer's pathology is the presence of insoluble protein deposits known as beta-amyloid on the surface of nerve cells, which results from the accumulation of soluble beta-amyloid in the brain. The effects of the disease are devastating to the patients as well as the caregivers, with significant associated health care costs. It is estimated that there are more than 5 million Americans and about 30 million people suffering from Alzheimer's disease world wide with the number expected to increase dramatically as the global population ages. Currently marketed drugs transiently affect some of the symptoms of the disease, but there are no drugs on the market today that slow or arrest the progression of the disease. These symptomatic drugs are projected to generate more than US$6 billion in sales by 2010, indicating both the size of the market and the demand for effective treatment beyond symptomatic improvements.

ABOUT OTCPICKS.COM

OTCPicks.com is an Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Profile Research Reports authored by our financial writers. We publish a daily Newsletter to subscribers, and we publish our Daily Market Movers Digest which is sent out on the M2 Presswire several times daily highlighting hot OTC and OTCBB stocks. To feature a company on our web site or in our daily Newsletter or Market Mover's Digest, please contact our publisher, Brian Dean at 972-546-3740, or via email at publisher@otcpicks.com.

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE: The OTCPicks.com employees are NOT Registered as an Investment Advisor in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold OTCPicks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. OTCPicks.com has been compensated eight thousand dollars by a third party (BlueWave Advisors) for PGOG advertising and promotional services. For a complete list of disclosures go to http://www.otcpicks.com/disclosure-details.htm. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCPicks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCPicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTCPicks.com and its affiliates are not registered investment advisors or a broker dealers. OTCPicks.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor's sole risk. OTCPicks.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTCPicks.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCPicks.com. OTCPicks.com owners may or may not hold positions in the companies that are profiled.

The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results.

Third Party Web Sites and Information:

OTCPicks.com and newsletter may provide hyperlinks to third party websites or access to third party content. OTCPicks.com does not control, endorse, or guarantee content found in such sites. You agree that OTCPicks.com is not responsible for any content, associated links, resources, or services associated with a third party site. You further agree that OTCPicks.com shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only.

CONTACT: Brian Dean, Publisher, OTCPicks.com Tel: +1 972 546 3740 e-mail: publisher@otcpicks.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

For full details for ADXS click here.

More News: Market Updates | Stock Alerts | All Trading News | Stock Index